Cefprozil


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : PO 500 mg/day, as single or in 2 divided doses, may increase to 500 mg bid. Duration: 10 days.
Dosage Details
Oral
Respiratory tract infections, Skin and skin structure infections
Adult: 500 mg daily as a single or in 2 divided doses, increased to 500 mg bid if necessary. Duration: 10 days.
Child: 6 mth to 2 yr For otitis media: 15 mg/kg 12 hrly. For acute sinusitis: 7.5 mg/kg or 15 mg/kg 12 hrly. For pharyngitis or tonsillitis: 7.5 mg/kg 12 hrly. >2 yr For skin and skin structure infections: 20 mg/kg daily. Max: 1 g daily.
Renal Impairment
CrCl Dosage
≤30 Reduce dose by 50%.
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Reconstitution
Add the amount of water specified on the container in 2 equal portions to provide a susp containing 125 mg or 250 mg per 5 mL. Shake the bottle after each addition.
Contraindications
Hypersensitivity to cefprozil or to other cephalosporins.
Special Precautions
History of hypersensitivity to penicillins and GI disease esp colitis. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, vomiting, abdominal pain, dyspepsia, flatulence, glossitis, mouth pain; rash, serum sickness-like reactions, erythema, exanthema, erythema multiforme, erythema nodosum, Stevens-Johnson syndrome, toxic epidermal necrolysis; dizziness, hyperactivity, headache, nervousness, insomnia, confusion, somnolence; increased AST (SGOT), ALT (SGPT), serum alkaline phosphatase, bilirubin and serum LDH levels; eosinophilia, decreased leukocyte count, agranulocytosis, aplastic anaemia, pancytopenia, haemolytic anaemia, haemorrhage; elevated BUN and serum creatinine, renal dysfunction, toxic nephropathy; vaginitis, genital pruritus, leucorrhoea, vag candidiasis, diaper rash, superinfection. Rarely, urticaria, pruritus, lightheadedness, cholestatic jaundice, neutropenia, thrombocytopenia, thrombocytosis, decreased haematocrit; fever, chills, tinnitus, sweating, visual field defects, angioedema, crying, generalised pain, back pain, leg pain; prolonged partial thromboplastin time, prothrombin time and prothrombin ratio.
Potentially Fatal: Anaphylaxis, pseudomembranous colitis.
MonitoringParameters
Monitor renal function and for signs of anaphylaxis during 1st dose.
Drug Interactions
May enhance the nephrotoxic effect of aminoglycosides. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May increase serum concentrations w/ probenecid.
Lab Interference
Positive direct antiglobulin (Coombs') test results. False-positive result in urine glucose determinations using cupric sulfate (e.g. Benedict's soln, Fehling's soln, Clinitest®). False-negative result in ferricyanide test for blood glucose.
Action
Description: Cefprozil inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Absorption: Well absorbed from the GI tract. Bioavailability: 90-95%. Time to peak plasma concentration: 1-2 hr.
Distribution: Widely distributed in body tissues. Enters breast milk. Plasma protein binding: Approx 35-45%.
Excretion: Via urine (approx 60%, as unchanged drug). Plasma half-life: 1-1.4 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C. Reconstituted powd for susp: Store between 2-8°C.
MIMS Class
ATC Classification
J01DC10 - cefprozil ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by MIMS based on Cefprozil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in